Remgro (REM) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
28 Mar, 2026Executive summary
Headline earnings per share rose 38.5% year-over-year to 931 cents, with headline earnings up 38.8% to R5,175 million, driven by strong contributions from Mediclinic, CIVH, Rainbow, and Heineken Beverages, and supported by portfolio optimization initiatives.
Interim dividend per share increased 80.2% to 173 cents, reflecting robust cash generation and a strengthened balance sheet.
Intrinsic net asset value per share (INAV) grew 1.6% to R297.03, with the share price up 14.8% to R181.61, narrowing the discount to INAV to 38.9%.
Portfolio simplification advanced with the CIVH Vodacom transaction, BAT stake sale, eMedia unbundling, and partial monetization of FirstRand, de-risking the balance sheet.
Operational resilience and disciplined execution underpinned value creation despite volatile macroeconomic and geopolitical conditions.
Financial highlights
Headline earnings up 38.8% to R5,175 million; headline EPS up 38.5% to 931 cents year-over-year.
Dividends received at the center increased by 34% to R2,428 million; special dividends of R2,800 million received.
INAV per share at R297.03, up 1.6% from June 2025; share price discount to INAV narrowed by 700bps to 38.9%.
Interim dividend per share increased 80.2% to 173 cents; payout ratio adjusted to 1.5x cover.
Cash at the centre rose to R12,028 million, up R3,666 million from June 2025, supported by increased dividends and CIVH pre-implementation dividend.
Outlook and guidance
Management remains confident in long-term portfolio growth potential despite macroeconomic volatility and geopolitical risks.
Focus remains on portfolio optimization, disciplined capital allocation, and ESG priorities to deliver sustainable growth.
Cautious capital allocation posture maintained; further dividend increases or share buybacks will depend on market conditions.
Economic recovery in South Africa depends on infrastructure, logistics, and energy reform.
The group maintains a resilient balance sheet and strategic liquidity to support future opportunities and withstand external shocks.
Latest events from Remgro
- HEPS expected to rise 36%–41% year-over-year for the six months ended 31 December 2025.REM
H1 2026 TU13 Mar 2026 - Headline earnings down 20%, dividend up 10%, with strong OUTsurance and RCL Foods results.REM
H2 202420 Jan 2026 - All resolutions passed as shareholders engaged on strategy, incentives, and global risks.REM
AGM 202412 Jan 2026 - Portfolio is 63% private, with growth led by Mediclinic and CIVH, and focus on ESG and performance.REM
CMD 202520 Dec 2025 - Headline earnings up 38.7%, INAV per share up 10.3%, and dividend up 20%.REM
H1 20251 Dec 2025 - Maziv's ZAR 38.75bn deal advances with regulatory support, CapEx, and BEE commitments.REM
Investor Update13 Nov 2025 - Headline earnings up 38.6%, ordinary dividend up 30.3%, and balance sheet fully de-geared.REM
H2 202516 Oct 2025